ResMed Inc. – Consensus ‘buy’ rating and 5.5% Upside Potential

Broker Ratings
[shareaholic app="share_buttons" id_name="post_below_content"]

ResMed Inc. which can be found using ticker (RMD) have now 8 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The target price High/Low ranges between $220.00 and $158.00 and has a mean target at $178.38. Given that the stocks previous close was at $169.05 this would indicate that there is a potential upside of 5.5%. It’s also worth noting that there is a 50 day moving average of $151.28 and the 200 day moving average is $188.74. The total market capitalization for the company now stands at 24.99B. The stock price for the company is currently is currently $169.91 USD

The potential market cap would be $26,371,751,335 based on the market consensus.

The company has a dividend yield of 2.05%. Other points of data to note are a P/E ratio of 27.63, revenue per share of $29.78 and a 12.22% return on assets.

ResMed Inc. is a holding company. The Company, through its subsidiaries, is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep-disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease and other chronic diseases. It also offers software solutions for a variety of out-of-hospital care providers. The Company has two segments: Sleep and Respiratory Care and the Software-as-a-Service. Sleep apnea includes obstructive sleep apnea and other respiratory disorders that occur during sleep. Its cloud-based digital health applications, along with its devices, are designed to provide connected care to improve patient outcomes. The Company’s portfolio of products includes ventilation devices, diagnostic products, mask systems, headgear and other accessories, dental devices and cloud-based software informatics solutions.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:

      Search

      Search